Wisp OMG! Cream (Sildenafil Cream) review: is it worth it?

What is Wisp OMG! Cream and who makes it?

OMG! Cream is a product from Wisp (legally Wisp, Inc.), a direct-to-consumer telehealth company focused on sexual and reproductive health. You complete an online medical questionnaire, a licensed provider reviews it (and may follow up by phone or secure chat), and if appropriate, a prescription is sent to a compounding pharmacy that ships the cream to your home in discreet packaging.

The "active" idea is sildenafil — the same molecule in Viagra and Revatio — but delivered topically rather than as a swallowed pill. Wisp sells two strengths: an Original formula with 1% sildenafil and an Extra Strength formula with 3% sildenafil. Each bottle is marketed as roughly 15 applications.

A critical distinction that Wisp itself makes clear: OMG! Cream is not the same as oral Viagra, and it is not an FDA-approved medication. There is currently *no* FDA-approved drug for female sexual arousal disorder (FSAD) (the FDA has approved flibanserin and bremelanotide for low *desire* — HSDD — which is a different problem). Because OMG! Cream is a compounded preparation, it does not go through FDA review for safety and efficacy the way a branded drug does. Compounded medications are legal and prescribed widely, but they are not individually FDA-evaluated, and formulations can vary by pharmacy.

It's also worth knowing the cream is not pure sildenafil in a base. Based on Wisp's own contraindication list, the compound also contains pentoxifylline (a vasodilator that improves blood flow) and ergoloid mesylate. That matters for who can safely use it (more below).

How is it supposed to work?

Sildenafil is a PDE5 inhibitor. By blocking the PDE5 enzyme, it preserves cyclic GMP, which relaxes smooth muscle and dilates blood vessels — increasing blood flow into erectile tissue. In men this engorges the penis; the same erectile tissue exists in the clitoris, labia, and vaginal walls. The theory behind topical sildenafil for women is that delivering it directly to genital tissue increases local blood flow, engorgement, lubrication, and sensitivity — the physical components of arousal — with much lower systemic absorption than a swallowed pill.

Two things follow from this mechanism, and both are important to understand honestly:

• It targets arousal and physical sensation, not desire. If your concern is low *libido* (wanting sex at all), a blood-flow cream is the wrong tool; that's the domain of desire-focused treatments. OMG! Cream is aimed at the woman who has interest but struggles with physical arousal, lubrication, or genital sensation.
• Topical does not mean instant or guaranteed. Wisp directs users to apply about 30 minutes before activity. Any "tingle" some formulations include produces an immediate sensory effect that is cosmetic, not pharmacological — it shouldn't be confused with the drug working.

What does the evidence actually show?

This is where an honest review separates itself from marketing. Topical sildenafil for women is a genuinely active area of research, but the strongest data come from a *specific 3.6% formulation* developed by Daré Bioscience — not from any compounded product, and not at exactly the 1% or 3% concentrations Wisp sells.

In the Phase 2b RESPOND trial of Sildenafil Cream 3.6% in premenopausal women with FSAD, the results were mixed and best described as "signal, not proof." The exploratory study randomized 200 participants (101 to sildenafil cream, 99 to placebo) across multiple U.S. sites with a 12-week double-blind dosing period. In the full intention-to-treat population, there were no statistically significant differences between the sildenafil and placebo groups on the co-primary or secondary efficacy endpoints. However, in an exploratory post-hoc subset — women whose enrollment diagnosis was FSAD *with or without concomitant decreased desire* — sildenafil cream produced a statistically significant improvement in the SFQ28 Arousal Sensation domain (P=.04) and significant improvement on several Female Sexual Distress Scale items (questions 3, 5, and 10; all P≤.04) (Clayton et al., *Obstet Gynecol* 2024;144(2):144-152; PMID 38889431). On the basis of this subgroup signal, the developer proposed a refined patient population and endpoints for Phase 3.

The accompanying safety publication is reassuring on tolerability: across the 12-week double-blind period, treatment-emergent adverse events occurred in about 29% of both the sildenafil and placebo groups (29.3% vs 29.8%, P=.76), all mild-to-moderate, with no serious adverse events, and partner exposure produced few events (Thurman et al., *The Journal of Sexual Medicine* 2024;21(9):793-799; PMID 39079074; DOI 10.1093/jsxmed/qdae089).

Three caveats that genuinely matter for OMG! Cream buyers:

1. The studied product is not the product Wisp sells. Daré's 3.6% cream is a defined investigational formulation. Wisp's compounded 1% and 3% creams (which also contain pentoxifylline and ergoloid mesylate) have not been tested in their own published randomized trials. Evidence for one formulation does not automatically transfer to another.
2. The headline efficacy was an exploratory subgroup, not the whole trial. The co-primary endpoints were not met in the full study population; the positive result came from a post-hoc subset, which is hypothesis-generating, not confirmatory. It is the reason a Phase 3 is needed before anyone can claim topical sildenafil "works" for FSAD in the regulatory sense.
3. Topical sildenafil for men (ED) is even thinner. Only a handful of small studies of topical or gel sildenafil exist in men, and the published evidence is limited and inconsistent compared with oral dosing. OMG! Cream is marketed for women; men seeking ED treatment have far better-evidenced options in oral PDE5 inhibitors.

Bottom line on evidence: the *mechanism* is sound, early human data are *encouraging for a specific subgroup of women*, and the *safety profile in trials was good* — but this is not a proven, FDA-cleared treatment, and you should set expectations accordingly.

How do you use it (dosing and timing)?

Wisp's instructions are straightforward: apply a small amount directly to the clitoral and vaginal area about 30 minutes before anticipated sexual activity, and gently massage it in. Wash your hands afterward, and avoid applying to broken or irritated skin. Each bottle is described as containing roughly 15 treatments.

Because there is no standardized, FDA-approved dosing for compounded topical sildenafil, "dose" here is effectively a thin application of whatever concentration you were prescribed. Many users reasonably start with the 1% Original formula and only consider the 3% Extra Strength if the lower strength feels insufficient — a sensible "lowest effective amount first" approach. Onset is individual; reports of feeling something quickly exist but should not be taken as a reliable timeline.

Side effects, warnings, and who should NOT use it

In trials of topical sildenafil cream, the most common complaint was application-site discomfort — local itching, redness, dryness, or scaling — which is usually mild and manageable. Notably, the Phase 2b safety data found that the low systemic absorption of the topical cream meant the classic oral-sildenafil side effects (headache, facial flushing) were not more common than placebo. Still, because some sildenafil can be absorbed — and more so with higher concentrations or broken skin — systemic PDE5-type effects such as headache, facial flushing, dizziness, or stomach upset remain theoretically possible and worth watching for.

The contraindications are not trivial, largely because the compound contains sildenafil *plus* pentoxifylline and ergoloid mesylate. Per Wisp's own safety guidance, you should not use OMG! Cream if you:

• Are allergic to sildenafil citrate, pentoxifylline, or ergoloid mesylate;
• Have retinitis pigmentosa, a history of recent cerebral or retinal hemorrhage, or peripheral vascular disease;
• Have coronary heart disease or uncontrolled high blood pressure;
• Have severe liver or kidney impairment;
• Are pregnant or breastfeeding (pentoxifylline is not recommended in pregnancy unless the benefit clearly outweighs the risk, and is excreted in breast milk).

The most dangerous interaction is with nitrates. Combining any sildenafil-containing product with nitrate medications (e.g., nitroglycerin) or with guanylate cyclase stimulators (e.g., riociguat) can cause a severe, potentially life-threatening drop in blood pressure (FDA sildenafil/Viagra prescribing information). Wisp also flags caution with certain blood pressure drugs, strong CYP3A4 inhibitors, ergot medications, and triptans within 24 hours.

Two practical, real-world cautions the marketing tends to gloss over:

• Partner and oral-sex exposure. It is a vaginal/clitoral cream. Whether a partner contacts it during oral sex, and what they ingest, is a fair question to raise with the prescribing provider — especially if the partner takes nitrates or has cardiovascular disease.
• Condom compatibility. Oil-containing topical creams can degrade latex. If you rely on latex condoms for contraception or STI prevention, confirm compatibility before assuming the cream is safe to combine with them.

This is exactly why a prescription gatekeeper is appropriate here — these are not concerns you'd want to navigate alone from an over-the-counter "arousal gel."

Who is it best for — and who should skip it?

Reasonable fit: premenopausal or healthy peri/postmenopausal women whose primary complaint is *physical arousal* — difficulty getting "turned on" physically, poor lubrication, or reduced genital sensation — who have interest in sex but feel the body isn't responding, and who have no cardiovascular contraindications. The trial subgroup that benefited most looked a lot like this.

Probably the wrong tool if: your core issue is low *desire* (you don't want sex), in which case desire-targeted treatments or addressing relationship, hormonal, mood, or medication causes (SSRIs are a common culprit) is more appropriate; if arousal trouble is driven by vaginal dryness from low estrogen, where vaginal moisturizers or local estrogen are better-evidenced and often cheaper; or if you have any of the cardiovascular, nitrate, or pregnancy contraindications above.

Skip entirely if: you take nitrates, have significant heart disease, or want an FDA-approved, evidence-backed treatment — OMG! Cream is neither approved nor definitively proven.

Cost, value, and access

Wisp prices OMG! Cream on a one-time or subscription basis, with subscription pricing advertised as starting around $11/month (billed across a multi-month plan); a single one-time bottle and multi-bottle options are also offered, and exact prices can change, so confirm current pricing on Wisp's site at checkout. The fee typically bundles the telehealth consult and discreet shipping, with no separate insurance billing — these compounded products are generally out of pocket, not covered by insurance.

On value: the price is low relative to many telehealth sexual-health products, and the included provider review adds a genuine safety layer over an unregulated OTC gel. The honest counterweight is that you are paying for a compounded product whose specific formulation hasn't been proven in its own trial, and individual response varies widely. For some women it may be a worthwhile, low-cost experiment; for others it will do little beyond a cosmetic sensory effect.

How does it compare to the alternatives?

• vs. an FDA-approved option: None exists for arousal disorder, so OMG! Cream isn't being "beaten" by an approved cream — but desire problems (HSDD) *do* have approved drugs (flibanserin, bremelanotide), which are a better path if desire is the real issue.
• vs. vaginal moisturizers / lubricants: For dryness alone, these are cheaper, OTC, and well-established. OMG! Cream only makes sense if the problem is genuinely blood-flow/arousal, not just slipperiness.
• vs. local estrogen (for menopausal dryness/arousal): For postmenopausal genitourinary symptoms, local vaginal estrogen is far better evidenced than topical sildenafil.
• vs. other telehealth "arousal" creams: Many competitors sell similar compounded sildenafil creams; the differentiators are price, the rigor of the medical review, and pharmacy quality — not a proprietary breakthrough.

The bottom line

Wisp OMG! Cream is a legitimately interesting, mechanistically reasonable, low-cost option for women whose specific problem is *physical arousal and genital responsiveness* — and the telehealth/provider model adds a real safety check that OTC arousal gels lack. But the honest framing is essential: it is a compounded, non-FDA-approved product; the best human evidence (Daré's 3.6% cream) is early-stage and missed its co-primary endpoints in the full trial, showing benefit only in an exploratory subgroup; and the formula carries real contraindications — above all the nitrate interaction — that make a prescriber's involvement appropriate, not optional. If your issue is arousal, you have no cardiovascular red flags, and you treat it as a reasonably priced trial with managed expectations, it's a defensible thing to try. If your issue is desire, dryness, or you want proven efficacy, your money is better spent elsewhere — and that's a conversation to have with your clinician before you buy.